IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

AstraZeneca248 enrolled

Overview

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.

Study Type

OBSERVATIONAL

Enrollment

248

Conditions

Carcinoma, Small Cell

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: -Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide. Exclusion Criteria: -Patients who have no treatment history with the product (i.e.,durvalumab)

Locations (18)

Research Site

Chiba, Japan

Research Site

Fukuoka, Japan

Research Site

Gunma, Japan

Outcomes

Primary Outcomes

Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)

Time frame: 16weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.